SAB Biotherapeutics (SABS)

Executive Summary

SAB Biotherapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary DiversitAb™ platform to develop fully human polyclonal antibodies. Unlike traditional monoclonal antibodies, the company's technology utilizes genetically engineered cattle that produce a broad, natural human antibody response upon immunization. This approach offers potential advantages in targeting complex diseases where polyclonal responses may be more effective. The lead candidate, SAB-142, is being developed for type 1 diabetes, aiming to modulate the autoimmune response without broad immunosuppression. The company previously advanced a COVID-19 polyclonal antibody therapeutic into clinical trials. As a publicly traded entity (NASDAQ: SABS), SAB Biotherapeutics continues to validate its platform through clinical studies, with a focus on immune and infectious diseases. The platform's ability to generate high-titer, multi-target antibodies positions it for applications in areas with significant unmet medical need, though the company remains in earlier stages of clinical development.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 data readout for SAB-142 in type 1 diabetes40% success
• Q4 2026FDA IND clearance for a new infectious disease program60% success
• TBDStrategic partnership or licensing deal for DiversitAb platform25% success